her2-neu

Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 with an IC50 of 1 μM, demonstrating 100- and 500-fold higher selectivity for ErbB2 over EGFR and PDGFR, respectively.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ monoclonal antibody inhibitor that targets human or rat HER2.

Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphy

HER2/neu (654-662) GP2 acetate is derived from the human epidermal growth factor receptor 2 (HER2-Neu, 654–662). HER2/neu (654-662) GP2 acetate induces HLA-A2-restricted cytotoxic T lymphocytes reactive to various epithelial cancers.

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin.

Fasnall HCl is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall HCl also shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin.

Hsp90-IN-16 is an HSP90 inhibitor that acts effectively and highly selectively on HER2-positive cancer cells.Hsp90-IN-16 inhibits the proliferation of HCC1954 breast cancer cells with an IC50 value of 6 μM.Hsp90-IN-16 inhibits HSP90 "client "proteins, including a key oncogenic receptor HER2/neu, induced apoptosis in cancer cells.

CPI-444 (V81444) is an antagonist of the adenosine A2A receptor.It reduces tumor area in mouse model of murine Her2/neu-expressing breast cancer.

TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2/neu, is utilized in the formulation of J-LEAPS vaccines [1].

TYVPANASL, a nine-amino-acid MHC I-binding epitope from HER2/neu for CD8 T cells, can be utilized in the development of J-LEAPS vaccines [1].

SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope, class II rat HER2/neu peptide designed for research on the class II HER2-DC1 vaccine [1].

SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2/neu peptide used in the investigation of class II HER2-DC1 vaccine studies [1].

IRGRILHDGAYSLTLQGLGIH TFA, a multi-epitope class II rat HER2/neu peptide, is utilized in the study of class II HER2-DC1 vaccines [1].

IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide used in HER2-DC1 vaccine research studies [1].

ELAAWCRWGFLLALLPPGIAG TFA (P5), a 21-amino-acid peptide (aa 5-25) originating from the rat HER2/neu protein, has been shown to elicit cytotoxic T lymphocyte (CTL) responses in mice with HER2-positive tumors [1].

ELAAWCRWGFLLALLPPGIAG (P5), a 21-amino acid peptide (aa 5-25) derivative of the rat HER2/neu protein, has been shown to elicit cytotoxic T lymphocyte (CTL) responses in mice with HER2-positive tumors [1].

Fasnall, a fatty acid synthase (FASN) inhibitor, exhibits an IC50 of 3.71 μM against the human recombinant enzyme. It halts tritiated acetate incorporation into lipids (IC50= 5.84 μM), boosts ceramide levels, and triggers lipid droplet formation in BT474 HER2+ breast cancer cells. Demonstrating antiproliferative effects on various breast cancer cell lines, including non-tumorigenic MCF-10A and tumorigenic MCF-7, MDA-MB-468, BT474, and SK-BR-3, its efficacy is directly linked to FASN expression in vitro. In murine models of HER2+ breast cancer, particularly the MMTV-Neu model, Fasnall significantly reduces tumor volume and extends survival. Furthermore, it enhances the efficacy of carboplatin in vivo, bolstering the objective response rate of stable disease from 25% with carboplatin alone to 88% when paired with Fasnall.

Biotin HER-2 substrate peptide serves as a substrate for the tyrosine kinases HER4 and HER2/NEU, with a Km value of 60 μm in the kinase domain of HER2/NEU.

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody that targets both HER2/neu and CD3. It functions by activating Fcγ type I/III receptors, which facilitates the formation of a tri-cell complex involving tumor cells, T cells, and accessory cells. This compound has been utilized in the research of breast cancer [1].